جست‌وجوی استاد و پژوهشگر

• Ophthalmology
• Retinal Degeneration
• Nanomedicine
• +۳ مورد دیگر

Dr. Ling Zhu is an Associate Professor and Senior Research Fellow at the Save Sight Institute, University of Sydney. He holds dual affiliations with the Centre for Drug Discovery Innovation and the University of Sydney Nano Institute. His research focuses on retinal diseases, including diabetic retinopathy, age-related macular degeneration, and macular telangiectasia type 2, combining clinical and basic research approaches. Dr. Zhu leads a lab with a postdoc, two research assistants, and one HDR student, emphasizing innovative techniques like human retinal explant culture and nanomedicine. Dr. Zhu obtained his PhD in Biochemistry from Rutgers University (USA) in 2008. His work has attracted over $2 million in research funding in the past five years and includes 93 publications (3590 citations, H-index 34). He is a major author in leading journals like eLife and Ophthalmology . Current research projects include preclinical RNA-LNP therapy for retinal degeneration, targeting retinal metabolism for macular diseases, and developing a 'Macula-on-a-Chip' drug screening platform. His expertise spans biochemistry, molecular biology, and translational nanomedicine. Key achievements include establishing human retinal explant models and advancing lipid nanoparticle-based drug delivery systems. Dr. Zhu collaborates widely, with projects addressing unmet clinical needs in ophthalmology and drug discovery.

Moira Whyteمشاهده پروفایل

استاد

• Respiratory medicine
• Inflammation
• Neutrophil biology
• +۵ مورد دیگر

Moira Whyte serves as Sir John Crofton Professor of Respiratory Medicine and Head of Edinburgh Medical School at the University of Edinburgh, while directing the MRC University of Edinburgh Centre for Inflammation Research. Her leadership spans clinical academia and major research initiatives focused on respiratory pathophysiology. Her educational background includes a 1st Class B.Sc. (1981), M.B., B.S. (1984), and Ph.D. (1993) from the University of London, complemented by professional qualifications: M.R.C.P. (1987), F.R.C.P. (1998), and F.Med.Sci. (2005) from the Academy of Medical Sciences. Whyte's research centers on neutrophil biology, macrophage function, and hypoxia signaling pathways in respiratory diseases. Her work explores how oxygen-sensing mechanisms like HIF pathways regulate immune cell function in COPD, pulmonary fibrosis, and bacterial infections, with particular focus on cellular metabolism and inflammation resolution. Analysis of her 15 most recent publications reveals consistent focus on neutrophil and macrophage biology within respiratory diseases, with growing emphasis on metabolic regulation of immune responses. Her work bridges basic science (using zebrafish models) with clinical applications, particularly in COPD and pulmonary fibrosis. Her scientific recognition includes: 2014 OBE for Services to Respiratory Medicine 2014 Foundation Fellow of the European Respiratory Society 2005 Fellow, Academy of Medical Sciences 2002 Tudor Edwards Lecturer of the Royal College of Physicians 1994 Wellcome Trust Advanced Fellowship 1989 MRC Clinical Training Fellowship Whyte directs substantial research funding, including a £6.4M Wellcome Trust Clinical PhD Programme (ECAT-Plus) and multiple grants investigating macrophage function in COPD, hypoxia pathways in pulmonary fibrosis, and neutrophilic inflammation regulation. Her collaborative approach is evident in multi-institutional projects like the EME-TIPAC study on pulmonary fibrosis. As Director of the MRC Centre for Inflammation Research, she leads a multidisciplinary team investigating fundamental mechanisms of inflammation across multiple disease contexts, with particular strength in respiratory immunology and translational applications.

Marshall J. Glesbyمشاهده پروفایل

استاد

• HIV Pathogenesis
• Aging in HIV Patients
• Co-infections
• +۵ مورد دیگر

Marshall J. Glesby is a Professor at Weill Cornell Medical College, affiliated with both the Department of Medicine and Population Health Sciences. His career spans over three decades, focusing on HIV pathogenesis, aging-related complications, and co-infections. He holds a Ph.D. from Johns Hopkins University School of Hygiene and Public Health (1997), an M.D. from Johns Hopkins University School of Medicine (1989), and a B.Sc. from McGill University (1985). Research Interests: His work integrates HIV, immunology, and public health, emphasizing co-infections, metabolic disorders, and cardiovascular complications. Recent studies explore geriatric syndromes, epigenetic aging, and biomarkers like extracellular vesicles in Long COVID and Alzheimer's disease. He leads clinical trials on Mpox severity scoring and HIV-kidney transplantation. Grants and Collaborations: Dr. Glesby is a key investigator for NIH-funded projects, including PORTENT (NIAID) and STRIVE (NIAID). He contributes to global HIV research networks like INSIGHT and ACTG, with subawards from the National Institute of Child Health & Human Development and NHLBI. External Relationships: He serves as a consultant for UpToDate, Inc., and collaborates with organizations such as the Northeast/Caribbean AIDS Education and Training Centers.

Anna G Orrمشاهده پروفایل

استادیار

• Neuroscience
• Neurodegenerative Diseases
• Astrocyte Biology
• +۵ مورد دیگر

Anna G Orr serves as Nan and Stephen Swid Assistant Professor of Frontotemporal Dementia Research and Assistant Professor of Neuroscience at Weill Cornell Medical College's Brain and Mind Research Institute since 2016, leading pioneering research on astrocyte biology in dementia pathogenesis. Her educational background includes: Ph.D. from Emory University (2008) B.S. from Allegheny College (2002) Dr. Orr's research program centers on astrocytic-neuronal interactions , mitochondrial signaling , and neuroimmune mechanisms through three interconnected pathways: neuroimmune , oxidative , and G protein-coupled signaling . Her lab investigates how these mechanisms influence neuroinflammation, protein aggregation, synaptic function, and behavioral outcomes in dementia, with parallel therapeutic discovery efforts targeting astrocytic pathways for novel dementia treatments. Analysis of her 15 most recent publications (2025-2010) reveals escalating focus on astrocyte-specific dementia mechanisms , particularly mitochondrial ROS signaling, sex-dimorphic memory effects, TDP-43 pathology interactions with antiviral pathways, and lipid dysregulation in neurodegeneration. Her work consistently bridges molecular discoveries with therapeutic applications, demonstrating increasing NIH funding support for translational approaches. Key scientific recognitions include: NIH K99/R00 Pathway to Independence Award (2017) Leon Levy Fellowship in Neuroscience (2021) Nan and Stephen Swid Endowed Professorship (2021) Outstanding Neuroscience Teaching Award (2021) Dr. Orr actively mentors eight trainees across career stages, including Ph.D. candidates Evelyn Hardin and Constance Zhou, while securing major NIH grants as Principal Investigator for projects like Uncovering Dementia-Related Lipid Alterations in Astrocytes (NIA 2024-2026) and Mitochondrial Complex III Free Radicals in Dementia Pathology (NIA 2020-2026), alongside collaborative awards from the Alzheimer's Association. Her Orr Lab maintains a dual focus on mechanistic astrocyte biology and therapeutic translation, with current projects examining astrocytic TDP-43 dysregulation, mitochondrial complex III signaling, and sex-specific memory mechanisms using advanced in vivo techniques and disease models.

Feyruz V. Rassoolمشاهده پروفایل

استاد

• DNA damage and repair
• Genomic instability
• Epigenetic therapy
• +۷ مورد دیگر

Feyruz V. Rassool is a Professor at the University of Maryland School of Medicine, with primary appointment in Radiation Oncology. She serves as Co-director of the Experimental Therapeutics Program at the University of Maryland Greenebaum Comprehensive Cancer Center (UMGCCC) and holds an adjunct Associate Professor position at VARI’s Center for Epigenetics. Her research focuses on DNA damage/repair pathways in cancer, particularly their therapeutic exploitation through PARP and DNMT inhibitors. Education: B.Sc. in Human Genetics (1983, University College London), Ph.D. in Biological Sciences (1990, Royal Postgraduate Medical School) Postdoctoral Training: University of Chicago (1990-1994) Her work explores the intersection of DNA repair , epigenetics , and mitochondrial dysfunction to develop novel therapies for breast, ovarian, lung, and leukemias. Key projects include STING-dependent interferon signaling , pathogen mimicry in cancer cells, and metastasis suppression through PARPi/epigenetic combinations. Dr. Rassool is part of the SU2C Epigenetics Dream Team and has secured multiple grants from NCI, NIH, and the Adelson Medical Research Foundation. Her recent preclinical studies with PARP/DNMT inhibitors are being translated into Phase I/II trials for AML and TNBC. Scientific Awards Ziskin Award (2012) NCI-SPORE Grant Co-Leader NIH/NCI P30 CA134274 Support Grant She has mentored 13 PhD/postgraduate researchers and collaborates on clinical trials with Pfizer, VARI-SU2C, and ASTRO. Her lab employs techniques like DNA repair assays , RNAseq , and mouse xenograft models to investigate mechanisms of action for epigenetic drugs.

• Metabolic Signaling
• Pancreatic Islet Biology
• Signal Transduction Pathways
• +۴ مورد دیگر

Dr Amin Ardestani , Senior Lecturer in Metabolic Signaling at the Biomedical Institute for Multimorbidity (BIM), Hull York Medical School (HYMS) , specializes in unraveling molecular mechanisms of pancreatic β-cell failure in diabetes. His research program identifies novel therapeutic targets through signal transduction studies in metabolic disorders. Bachelor's in Biology, Tarbiat Moalem University (2004) Master's in Biochemistry, Institute of Biochemistry and Biophysics (2007) PhD in Biology, University of Bremen (2013) Junior Group Leader at University of Bremen (2014-2023) Research focuses on Hippo and mTOR signaling pathways in β-cell biology, autoimmunity, and regeneration. His work bridges mechanistic biology with drug discovery for diabetes, with significant findings on PHLPP1/2 phosphatases and MST1/2 kinases. Recent publications highlight therapeutic strategies for β-cell protection , including small molecule inhibitors (e.g., MST1/2 inhibitors) and metabolic enzyme modulation (LDHA). Collaborative studies explore SARS-CoV-2 interactions with pancreatic cells and cross-talk between acinar and β-cells in diabetes. 2019 JDRF Advanced Postdoctoral Fellowship 2018 Impulse grant & Career Advancement Award 2017 Early Investigators awards (Endocrine Society, EFSD/Lilly Programme) 2014 Albert Renold Fellowship & Bremer Studienpreis Professional roles include Editorial Board Member at Scientific Reports and Associate Editor at Frontiers in Endocrinology . He reviews grants for DFG, Diabetes UK, and ISF, and evaluates manuscripts for top-tier journals like Cell Metabolism and Nature Communications.

• Radiation Oncology
• Cancer Biology
• Tumor Microenvironment
• +۳ مورد دیگر

Geoff Higgins is a Professor of Clinical Oncology at the University of Oxford, where he leads the Higgins Group in the Department of Oncology. He is also the Malcolm & Margaret Howat Professor of Clinical Oncology and an Honorary Consultant Clinical Oncologist at Oxford University Hospitals NHS Trust. His research focuses on enhancing radiotherapy efficacy through laboratory and clinical investigations, including repurposing existing compounds and developing novel treatments. MBChB, MRCP, FRCR, DPhil Pharmacology & Medicine, University of Edinburgh (1997-2000) Research Interests: Higgins' work addresses the tumor microenvironment, particularly hypoxia and genomic instability in cancer cells. His team explores combination therapies with radiotherapy, such as mitochondrial inhibitors and Polθ-targeting agents, aiming to translate discoveries into clinical trials with functional imaging and genomic monitoring. Key Publications: Recent studies highlight his group's breakthroughs in radiosensitization mechanisms, including Polθ inhibition for BRCA-deficient cancers and Atovaquone's role in tumor oxygenation. These works span disciplines from molecular biology to clinical translation. Honors: Clinician Scientist Fellowship (Cancer Research UK) Advanced Clinician Scientist Fellowship (Cancer Research UK) Royal College of Radiologists/CRUK Clinical Research Fellowship Academic Leadership: Higgins supervises DPhil and MRes students while mentoring postdoctoral researchers. Former trainees now hold prestigious roles at institutions like Memorial Sloan Kettering Cancer Center and Harvard University. His collaborative network includes the CRUK National Cancer Imaging Translational Accelerator, where he serves as joint-lead investigator.

Giel van Doorenمشاهده پروفایل

دانشیار

• Cell Biology
• Parasitology
• Molecular Biology
• +۳ مورد دیگر

Giel van Dooren is an Associate Professor at the Research School of Biology , Australian National University. His research focuses on the cell biology and metabolism of apicomplexan parasites , particularly Toxoplasma gondii and Plasmodium falciparum , aiming to develop novel therapeutic strategies against these pathogens. Education: Bachelor of Arts/Bachelor of Science (University of Melbourne, 2000), PhD (University of Melbourne, 2005) His work explores three core areas: Nutrient acquisition (plasma membrane transporters), Mitochondrial biology (electron transport chain inhibitors, apicoplast-mitochondrion metabolic integration), and Toxoplasma life cycle (felid host genetics). Collaborations include Kiaran Kirk , Adele Lehane , Alex Maier , and Kevin Saliba . Recent publications highlight advancements in understanding mitochondrial transporter functions , divergent respiratory complexes , and nutrient pathway drug targets . His lab actively seeks innovative tools for combating parasitic diseases through molecular physiology and metabolomics. Scientific Awards: College of Science Dean’s Commendation for Excellence in Education - Teaching Excellence (2024) College of Science Dean’s Commendation for Excellence in Education - Outstanding Contribution to Student Learning (2023) Bancroft-Mackerras Medal of the Australian Society for Parasitology (2021) College of Science Dean’s Commendation for Excellence in Education (2020, 2020) Grants & Projects: Na+-dysregulating antimalarials: PfATP4 physiology (2024-2027) Metal transporters in Toxoplasma gondii (2023-2026) Amino acid acquisition in Apicomplexans (2023-2025) Targeting mitochondrial ETC in parasites (2020-2023) Regulating nutrient uptake in intracellular parasites (2020-2022)

Andrew Bassettمشاهده پروفایل

پژوهشگر

• Genome Engineering
• Neurodegenerative Diseases
• Stem Cell Research
• +۵ مورد دیگر

Dr. Andrew Bassett serves as Head of the Cellular and Gene Editing Research group at the Wellcome Sanger Institute, where he develops cutting-edge genome engineering techniques using human pluripotent stem cells to investigate neurodegenerative diseases including Alzheimer's and Parkinson's. His work focuses on scaling genetic screening approaches and improving CRISPR specificity for modeling complex disease mechanisms. His academic training includes: PhD at the MRC Laboratory of Molecular Biology (MRC-LMB) with Andrew Travers on chromatin remodelling in heterochromatin formation Postdoctoral research with David Baulcombe at the University of Cambridge studying small RNA roles in chromatin modification Additional postdoctoral work with Chris Ponting at the MRC Functional Genomics Unit (MRC-FGU) in Oxford, where he pioneered CRISPR applications in Drosophila Bassett's research program centers on developing advanced genome engineering methodologies for precise modulation of gene expression networks during development and neurodegeneration. His group specializes in creating complex editing events (SNPs, paired knockouts, enhancer perturbations) within iPSC-derived models, with particular emphasis on epigenetic regulation and transcriptional control. Current projects integrate single-cell 'omics and phenotypic assays to decode genetic causes of neurodegenerative disorders through the OpenTargets consortium. Analysis of his 15 most recent publications reveals dominant trends in CRISPR technology development (35%), neurodegenerative disease modeling (30%), and single-cell functional genomics (25%). His work consistently bridges methodological innovation with disease mechanism studies, increasingly incorporating multi-omics approaches and expanding into cancer immunology and infectious disease applications since 2022. As group leader, Bassett mentors postdoctoral researchers and PhD students while securing major funding for genome engineering initiatives. His team operates within the Sanger Institute's Cellular Operations division and maintains critical partnerships with the OpenTargets consortium for therapeutic target validation. The laboratory specializes in high-throughput screening platforms using iPSC-derived neural and microglial models, with recent methodological advances including scSNV-seq and ONE-STEP tagging systems that significantly enhance precision genome editing capabilities.

• Virology
• Molecular Pathology
• Host-Pathogen Interactions
• +۵ مورد دیگر

Dr. Richard Y. Zhao is a tenured Professor in the Department of Pathology and Microbiology-Immunology at the University of Maryland School of Medicine. His research combines molecular biology, fission yeast genetics, mammalian biology, and virology to study virus-host interactions, particularly for HIV and Zika virus. He previously held academic positions at Northwestern University and Columbia University and has contributed to over 120 peer-reviewed articles. B.S., China Oceanography University (1981) M.S., Oregon State University (1995) Ph.D., Oregon State University (1991) Postdoctoral Training, Columbia University (1991-1992) Dr. Zhao's research focuses on: Virus-host interactions and pathogenicity High-throughput drug screening for antivirals Role of viral proteins in neuroinflammation and cancer Translational genomics in precision medicine His recent publications highlight SARS-CoV-2 ORF3a, Zika envelope proteins, and HIV protease inhibitors, emphasizing host-pathogen mechanisms across species. He has served on NIH panels and editorial boards for journals like Cell Research and Retrovirology . Scientific awards include: Fellow, American Academy of Microbiology (2019) Bernard L Mirkin Endowed Chair (2001-2004) Honorary Director, Shandong Gallo Institute (2009) Distinguished Service from SCBA (2015) Outstanding Service from CBA-USA (2016) Dr. Zhao also contributes to clinical diagnostics and personalized medicine through molecular testing and pharmacogenetics programs.

Dario Alessiمشاهده پروفایل

استاد

• Protein Phosphorylation
• Ubiquitylation Pathways
• Parkinson's Disease
• +۳ مورد دیگر

Professor Dario Alessi is a leading academic at the University of Dundee's School of Life Sciences, serving as the Director of the MRC Protein Phosphorylation Unit (MRC PPU) and Professor of Signal Transduction. He earned his BSc (1988) and PhD (1991) from the University of Birmingham. His research focuses on protein phosphorylation and ubiquitylation pathways, particularly the LRRK2 kinase pathway linked to Parkinson's disease. He has made groundbreaking contributions to understanding LRRK2's role in neurodegeneration, including its interaction with Rab proteins and scaffolding molecules like RILPL1. School of Life Sciences, University of Dundee MRC PPU Director since 2012 Signal Transduction Therapy Unit Director His work combines molecular biology, biochemistry, and collaborative industry partnerships to advance therapeutic strategies for Parkinson's disease. Key research areas include LRRK2 activation mechanisms, Rab protein phosphorylation, and lysosomal dysfunction. Alessi has trained over 30 graduate students and 40 postdocs, many now in academic and industry leadership roles. Notable awards include the EMBO Gold Medal (2005), the Robert A. Pritzker Prize for Leadership in Parkinson’s Research (2023), and an OBE (2023) for contributions to medical science. His lab promotes open science, sharing reagents and protocols globally through platforms like MRC Pure Agents and LRRK2.bio. Current projects include investigating novel mitochondrial and organelle biology in Parkinson’s, developing biomarkers, and advancing LRRK2 inhibitors through clinical trials. Collaborations span the Michael J. Fox Foundation, Aligning Science Across Parkinson’s, and the UK Dementia Research Initiative.

Rick T. Dobrowskyمشاهده پروفایل

استاد

• Diabetic neuropathy
• Molecular chaperones
• Neurotrophin signaling
• +۳ مورد دیگر

Rick T. Dobrowsky is a Professor in the Department of Pharmacology & Toxicology at the University of Kansas School of Pharmacy. He also serves as Director of the Graduate Program in Neuroscience. His research focuses on diabetic neuropathy and molecular chaperones, exploring how hyperglycemia impacts neurotrophin signaling and mitochondrial function in peripheral nerves. Education: Ph.D. in Pharmacology, North Carolina State University (1990) Postdoctoral Training at Duke University Medical Center (1995) Research Interests: His work examines molecular mechanisms underlying diabetic neuropathy, including neuregulin signaling, mitochondrial proteome changes, and the role of molecular chaperones like Hsp70 and Hsp90. Current projects investigate how hyperglycemia alters IGF-1 signaling and neuregulinism to drive neuropathic damage. Publications: Recent work highlights therapies targeting molecular chaperones to treat diabetic neuropathy and Charcot-Marie-Tooth disease, including cemdomespib and noviomimetic compounds. Key findings include improved mitochondrial function and reduced demyelination in animal models. Advising & Grants: He has advised students like Sukhmanjit Kaur and Yssa Rodriguez. His lab collaborates on NIH-funded projects exploring mitochondrial dysfunction in diabetes and molecular chaperone-based therapies. Labs: Director of the Dobrowsky Lab, which studies signaling pathways in nerve degeneration and develops novel therapeutic approaches for peripheral neuropathies.

Mercedes Taylorمشاهده پروفایل

استادیار

• Inorganic and Organic Synthesis
• Porous Materials
• Supramolecular Assembly
• +۳ مورد دیگر

Dr. Mercedes Taylor is an Assistant Professor in the Department of Chemistry and Biochemistry at the University of Maryland, College Park. She holds the Nathan Drake Faculty Fellowship. Previously, she was a Jill Hruby Fellow in National Security Science and Engineering at Sandia National Labs (2018–2021) and a Post-Baccalaureate Intramural Research Training Awardee at the NIH (2011–2013). She earned her Ph.D. in Chemistry from UC Berkeley (2018) and a B.A. in Chemistry from Amherst College (2011). Her research focuses on synthesizing novel materials like supramolecular cages, covalent organic frameworks, and porous polymers for applications in water purification and critical metal capture. Her lab emphasizes controlling material structure to achieve selectivity for target molecules and enhance aqueous stability. Key projects include ion separations, environmental remediation, and energy storage solutions. Dr. Taylor’s work has been recognized through awards such as the 2024 Doctoral New Investigator Award (ACS), 2023 DOE Separation Science Core Award, and the 2023 Moore Inventor Fellowship. She mentors a dynamic research group, including graduate students and post-baccalaureate researchers, and actively engages in interdisciplinary collaborations. Her lab is part of the Taylor Group at UMD, which develops advanced materials for ion capture and water treatment. Alumni of her group include researchers at Sandia National Labs and academic institutions, contributing to both industry and academia.

Pierre Maechlerمشاهده پروفایل

استاد

• Mitochondrial metabolism
• Beta-cell function
• Diabetes research
• +۵ مورد دیگر

Pierre Maechler is a Professor at the University of Geneva's Faculty of Medicine in the Department of Cell Physiology and Metabolism. His research focuses on mitochondrial metabolism in pancreatic beta cells and its critical role in diabetes pathogenesis, with particular emphasis on glutamate dehydrogenase function and regulation. His laboratory investigates the molecular mechanisms of insulin secretion and beta-cell failure in Type 2 diabetes. Maechler's research interests span mitochondrial metabolism, energy homeostasis, and the molecular pathways linking nutrient sensing to insulin secretion. His work has established crucial connections between glutamate metabolism, beta-cell function, and diabetes development. He investigates how metabolic stressors like glucotoxicity and lipotoxicity impair beta-cell function through mitochondrial dysfunction. His research has expanded to include the role of glutamate dehydrogenase in multiple organs including brain, liver, and muscle, revealing systemic metabolic implications. Analysis of Maechler's publication record shows a sustained focus on beta-cell metabolism with evolving scope. Early work established fundamental mechanisms of glutamate signaling in insulin secretion, while recent publications demonstrate expansion into multi-organ metabolic regulation. His research has identified novel biomarkers for beta-cell mass, explored therapeutic targets for diabetes, and revealed unexpected roles for glutamate dehydrogenase in diverse physiological processes from muscle regeneration to brain function. The consistent thread through his work is understanding how mitochondrial metabolism governs cellular and systemic energy homeostasis. Professor Maechler has mentored numerous PhD students and postdoctoral fellows who have gone on to publish significant work in diabetes research. His laboratory collaborates extensively with clinical researchers to translate basic findings into potential therapeutic approaches for diabetes. Funding for his work likely comes from Swiss National Science Foundation and other European research agencies, supporting investigations into metabolic diseases. Maechler leads the Mitochondria and Energy Metabolism research group at the University of Geneva. His team employs a multidisciplinary approach combining molecular biology, metabolomics, and physiology to investigate metabolic regulation in health and disease. The laboratory maintains strong connections with clinical diabetes researchers, facilitating translational applications of their findings. Current work focuses on identifying novel therapeutic targets for preserving beta-cell function in diabetes.

David Walkerمشاهده پروفایل

استاد

• Aging
• Mitochondrial Biology
• Neurodegeneration
• +۳ مورد دیگر

David Walker is a Professor and Vice Chair of Academic Personnel in the Department of Integrative Biology and Physiology at the University of California, Los Angeles. He leads a research lab focused on understanding the molecular and cellular basis of aging, utilizing Drosophila melanogaster to investigate mechanisms such as mitochondrial dysfunction, autophagy, and intestinal barrier integrity. His work aims to identify therapeutic targets for age-related diseases. Education: B.S., Genetics, Queen's University Belfast (1995) MRes, Molecular Biology, University of Manchester (1996) Ph.D., Genetics, University of Manchester (2000) Walker's research interests center on the biological processes driving aging, with emphasis on mitochondrial dynamics, neurodegeneration, and gut-microbiota interactions. His lab employs genetic, molecular, and physiological approaches in Drosophila to dissect how cellular deterioration impacts lifespan and healthspan, bridging insights to human aging pathologies. Key themes include the role of autophagy adaptors (e.g., p62/SQSTM1), mitochondrial fission, and intestinal homeostasis in longevity. His recent publications (2014–2024) reveal a consistent focus on brain aging, mitophagy, and gut-brain axis disruptions, with trends toward identifying midlife interventions for healthspan extension. Articles frequently integrate cellular stress responses, metabolic regulation, and neurodegeneration, highlighting Drosophila as a versatile model for translational aging research. No scientific awards, prizes, or fellowships are mentioned in the provided text. While specific grants or student advisees are not detailed, Walker's lab actively mentors researchers and contributes to collaborative projects on aging mechanisms. Future directions may involve exploring mitochondrial-immune interactions and novel longevity pathways. Walker directs a Drosophila-focused laboratory at UCLA, emphasizing genetic screens and mechanistic studies to uncover evolutionarily conserved aging pathways. The team investigates tissue-specific aging cascades, including neuronal and intestinal systems, to develop strategies for mitigating age-related decline.